Pages that link to "Q44426227"

The following pages link to Meaningful effect size and patterns of response of the transition dyspnea index (Q44426227):

Displaying 26 items.

• Tiotropium versus placebo for chronic obstructive pulmonary disease (Q24194833) (← links)
• Tiotropium versus placebo for chronic obstructive pulmonary disease (Q24202175) (← links)
• A randomised, open-label study of umeclidinium versus glycopyrronium in patients with COPD (Q28596637) (← links)
• Extrafine beclomethasone/formoterol compared to fluticasone/salmeterol combination therapy in COPD (Q33558856) (← links)
• Long-term results of diaphragmatic plication in adults with unilateral diaphragm paralysis (Q34375533) (← links)
• Indacaterol on dyspnea in chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized placebo-controlled trials (Q34686851) (← links)
• Tiotropium: a bronchodilator for chronic obstructive pulmonary disease (Q36200675) (← links)
• The MCID of the transition dyspnea index is a total score of one unit (Q36669430) (← links)
• Two-year pulmonary safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 2 diabetes (Q36841961) (← links)
• Role of tiotropium in the treatment of COPD. (Q37017516) (← links)
• Impact of frequency of COPD exacerbations on pulmonary function, health status and clinical outcomes (Q37284889) (← links)
• New developments in the management of COPD: clinical utility of indacaterol 75 μg. (Q37390883) (← links)
• Minimally important differences in the Mahler's Transition Dyspnoea Index in a large randomized controlled trial--results from the Scleroderma Lung Study (Q37421246) (← links)
• Measurement of breathlessness in clinical trials in patients with chronic heart failure: the need for a standardized approach: a systematic review (Q37677389) (← links)
• Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents (Q37804908) (← links)
• Indacaterol 75 μg once daily for the treatment of patients with chronic obstructive pulmonary disease: a North American perspective (Q38072277) (← links)
• Comparison of distribution- and anchor-based approaches to infer changes in health-related quality of life of prostate cancer survivors (Q40026261) (← links)
• Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD (Q42694041) (← links)
• Longitudinal changes in patient-reported dyspnea in patients with COPD. (Q46075418) (← links)
• Cost-effectiveness analysis of tiotropium compared to ipratropium and salmeterol (Q46512235) (← links)
• Efficacy of indacaterol 75 μg once-daily on dyspnea and health status: results of two double-blind, placebo-controlled 12-week studies (Q46942791) (← links)
• Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trial (Q48293345) (← links)
• Validity of a Self-administered Questionnaire Version of the Transition Dyspnea Index in Patients with COPD. (Q51066326) (← links)
• Effect of Indacaterol on Dynamic Lung Hyperinflation and Breathlessness in Hyperinflated Patients with COPD (Q84599382) (← links)
• [Validation study of the BDI/TDI scores in chronic obstructive pulmonary disease] (Q84969659) (← links)
• Safety and Adverse Events after Targeted Lung Denervation for Symptomatic Moderate to Severe Chronic Obstructive Pulmonary Disease (AIRFLOW). A Multicenter Randomized Controlled Clinical Trial (Q92566839) (← links)